{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:19:43Z","timestamp":1784809183846,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013374","name":"NIHR School for Primary Care Research","doi-asserted-by":"publisher","award":["Doctoral Studentship"],"award-info":[{"award-number":["Doctoral Studentship"]}],"id":[{"id":"10.13039\/501100013374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013374","name":"NIHR School for Primary Care Research","doi-asserted-by":"publisher","award":["Evidence Synthesis Working Group no. 390"],"award-info":[{"award-number":["Evidence Synthesis Working Group no. 390"]}],"id":[{"id":"10.13039\/501100013374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The risks of harms from opioids increase substantially at high doses, and high-dose prescribing has increased in primary care. However, little is known about what leads to high-dose prescribing, and studies exploring this have not been synthesized. We, therefore, systematically synthesized factors associated with the prescribing of high-dose opioids in primary care.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a systematic review of observational studies in high-income countries that used patient-level primary care data and explored any factor(s) in people for whom opioids were prescribed, stratified by oral morphine equivalents (OME). We defined high doses as \u2265\u200990 OME mg\/day. We searched MEDLINE, Embase, Web of Science, reference lists, forward citations, and conference proceedings from database inception to 5 April 2019. Two investigators independently screened studies, extracted data, and appraised the quality of included studies using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. We pooled data on factors using random effects meta-analyses and reported relative risks (RR) or mean differences with 95% confidence intervals (CI) where appropriate. We also performed a number needed to harm (NNT<jats:sub>H<\/jats:sub>) calculation on factors when applicable.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We included six studies with a total of 4,248,119 participants taking opioids, of whom 3.64% (<jats:italic>n<\/jats:italic>\u2009=\u2009154,749) were taking high doses. The majority of included studies (<jats:italic>n<\/jats:italic>\u2009=\u20094) were conducted in the USA, one in Australia and one in the UK. The largest study (<jats:italic>n<\/jats:italic>\u2009=\u20094,046,275) was from the USA. Included studies were graded as having fair to good quality evidence. The co-prescription of benzodiazepines (RR 3.27, 95% CI 1.32 to 8.13, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200999.9%), depression (RR 1.38, 95% CI 1.27 to 1.51, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%), emergency department visits (RR 1.53, 95% CI 1.46 to 1.61, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%, NNT<jats:sub>H<\/jats:sub> 15, 95% CI 12 to 20), unemployment (RR 1.44, 95% CI 1.27 to 1.63, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%), and male gender (RR 1.21, 95% CI 1.14 to 1.28, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200978.6%) were significantly associated with the prescribing of high-dose opioids in primary care.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>High doses of opioids are associated with greater risks of harms. Associated factors such as the co-prescription of benzodiazepines and depression identify priority areas that should be considered when selecting, identifying, and managing people taking high-dose opioids in primary care. Coordinated strategies and services that promote the safe prescribing of opioids are needed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Study registration<\/jats:title>\n<jats:p>PROSPERO, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=88057\">CRD42018088057<\/jats:ext-link><\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12916-020-01528-7","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T02:02:34Z","timestamp":1585533754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Factors associated with the prescribing of high-dose opioids in primary care: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-5620","authenticated-orcid":false,"given":"Georgia C.","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal R.","family":"Mahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonny B.","family":"Muthee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"DeVito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Koshiaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey K.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Goldacre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"1528_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.genhosppsych.2012.06.018","volume":"34","author":"JO Merrill","year":"2012","unstructured":"Merrill JO, Von Korff M, Banta-Green CJ, Sullivan MD, Saunders KW, Campbell CI, et al. Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients. Gen Hosp Psychiatry. 2012;34:581\u20137. https:\/\/doi.org\/10.1016\/j.genhosppsych.2012.06.018.","journal-title":"Gen Hosp Psychiatry"},{"key":"1528_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jpain.2016.12.004","volume":"18","author":"BJ Morasco","year":"2017","unstructured":"Morasco BJ, Yarborough BJ, Smith NX, Dobscha SK, Deyo RA, Perrin NA, et al. Higher prescription opioid dose is associated with worse patient-reported pain outcomes and more health care utilization. J Pain. 2017;18:437\u201345. https:\/\/doi.org\/10.1016\/j.jpain.2016.12.004.","journal-title":"J Pain"},{"key":"1528_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/archinternmed.2011.117","volume":"171","author":"T Gomes","year":"2011","unstructured":"Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171:686\u201391. https:\/\/doi.org\/10.1001\/archinternmed.2011.117.","journal-title":"Arch Intern Med"},{"key":"1528_CR4","doi-asserted-by":"publisher","unstructured":"Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018;16(1):69. https:\/\/doi.org\/10.1186\/s12916-018-1058-y.","DOI":"10.1186\/s12916-018-1058-y"},{"key":"1528_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2215-0366(18)30471-1","volume":"6","author":"HJ Curtis","year":"2019","unstructured":"Curtis HJ, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid prescribing trends and geographical variation in England, 1998-2018: a retrospective database study. Lancet Psychi. 2019;6:140\u201350. https:\/\/doi.org\/10.1016\/S2215-0366(18)30471-1.","journal-title":"Lancet Psychi"},{"key":"1528_CR6","first-page":"826","volume":"60","author":"T Gomes","year":"2014","unstructured":"Gomes T, Mamdani MM, Paterson JM, Dhalla IA, Juurlink DN. Trends in high-dose opioid prescribing in Canada. Can Fam Physician. 2014;60:826\u201332 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25217680.","journal-title":"Can Fam Physician"},{"key":"1528_CR7","doi-asserted-by":"publisher","unstructured":"Lalic S, Gisev N, Bell JS, Ilom\u00e4ki J. Transition to high-dose or strong opioids: a population-based study of people initiating opioids in Australia. Addiction. 2019. https:\/\/doi.org\/10.1111\/add.14926.","DOI":"10.1111\/add.14926"},{"key":"1528_CR8","doi-asserted-by":"publisher","first-page":"CD012299","DOI":"10.1002\/14651858.CD012299.pub2","volume":"10","author":"C Els","year":"2017","unstructured":"Els C, Jackson TD, Hagtvedt R, Kunyk D, Sonnenberg B, Lappi VG, et al. High-dose opioids for chronic non-cancer pain: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;10:CD012299. https:\/\/doi.org\/10.1002\/14651858.CD012299.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1528_CR9","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. JAMA. 2016;315:1624\u201345. https:\/\/doi.org\/10.1001\/jama.2016.1464.","journal-title":"JAMA."},{"key":"1528_CR10","volume-title":"Opioids aware: a resource for patients and healthcare professionals to support prescribing of opioid medicines for pain","author":"FPM","year":"2018","unstructured":"FPM. Opioids aware: a resource for patients and healthcare professionals to support prescribing of opioid medicines for pain. 2018. https:\/\/www.rcoa.ac.uk\/faculty-of-pain-medicine\/opioids-aware LB - CYEsL."},{"key":"1528_CR11","volume-title":"The 2017 Canadian guideline for opioids for chronic non-cancer pain","author":"J Busse","year":"2017","unstructured":"Busse J, Guyatt G, Carrasco A. The 2017 Canadian guideline for opioids for chronic non-cancer pain. 2017. http:\/\/cpspei.ca\/wp-content\/uploads\/2012\/01\/Guideline-for-Opioids-for-Chronic-Non-Cancer-Pain-McMaster-May-2017-Approved-by-Council-June-19-2017.pdf LB - XXNMx."},{"key":"1528_CR12","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1001\/jama.2019.5188","volume":"321","author":"R Rubin","year":"2019","unstructured":"Rubin R. Limits on opioid prescribing leave patients with chronic pain vulnerable. JAMA. 2019;321:2059\u201362.","journal-title":"JAMA"},{"key":"1528_CR13","doi-asserted-by":"publisher","unstructured":"Martin J, Cunliffe J, D\u00e9cary-H\u00e9tu D, Aldridge J. Effect of restricting the legal supply of prescription opioids on buying through online illicit marketplaces: interrupted time series analysis. BMJ. 2018;361. https:\/\/doi.org\/10.1136\/bmj.k2270.","DOI":"10.1136\/bmj.k2270"},{"key":"1528_CR14","doi-asserted-by":"publisher","first-page":"e196928","DOI":"10.1001\/jamanetworkopen.2019.6928","volume":"2","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Healy N, Garpestad C, Jannausch M, Tipirneni R, Bohnert ASB. Access to primary care clinics for patients with chronic pain receiving opioids. JAMA Netw Open. 2019;2:e196928. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6928.","journal-title":"JAMA Netw Open"},{"key":"1528_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","volume":"10","author":"H Breivik","year":"2006","unstructured":"Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287\u2013333. https:\/\/doi.org\/10.1016\/j.ejpain.2005.06.009.","journal-title":"Eur J Pain"},{"key":"1528_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1525-1497.2006.00412.x","volume":"21","author":"CC Upshur","year":"2006","unstructured":"Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21:652\u20135. https:\/\/doi.org\/10.1111\/j.1525-1497.2006.00412.x.","journal-title":"J Gen Intern Med"},{"key":"1528_CR17","first-page":"393","volume":"6","author":"M Johnson","year":"2013","unstructured":"Johnson M, Collett B, Castro-Lopes JM. The challenges of pain management in primary care: a pan-European survey. J Pain Res. 2013;6:393\u2013401.","journal-title":"J Pain Res"},{"key":"1528_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/14651858.CD010323.pub3","volume":"82","author":"C Eccleston","year":"2017","unstructured":"Eccleston C, Fisher E, Thomas KH, Hearn L, Derry S, Stannard C, et al. Interventions for the reduction of prescribed opioid use in chronic non-cancer pain. Cochrane Database Syst Rev. 2017;82:448. https:\/\/doi.org\/10.1002\/14651858.CD010323.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1528_CR19","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration LB - JOCqf","author":"JPTGS Higgins","year":"2011","unstructured":"Higgins JPTGS. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration LB - JOCqf; 2011."},{"key":"1528_CR20","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008\u201312 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10789670.","journal-title":"JAMA."},{"key":"1528_CR21","unstructured":"NHS England. Primary care services. 2019. https:\/\/www.england.nhs.uk\/participation\/get-involved\/how\/primarycare\/. Accessed 17 June 2019."},{"key":"1528_CR22","volume-title":"Country and lending groups","author":"Group WB","year":"2017","unstructured":"Group WB. Country and lending groups. 2017. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups LB - 6pxb6."},{"key":"1528_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/0003-4819-160-1-201401070-00732","volume":"160","author":"TK Nuckols","year":"2014","unstructured":"Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160:38\u201347. https:\/\/doi.org\/10.7326\/0003-4819-160-1-201401070-00732.","journal-title":"Ann Intern Med"},{"key":"1528_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/pds.4168","volume":"26","author":"S Nielsen","year":"2017","unstructured":"Nielsen S, Gisev N, Bruno R, Hall W, Cohen M, Larance B, et al. Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiol Drug Saf. 2017;26:587\u201391. https:\/\/doi.org\/10.1002\/pds.4168.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1528_CR25","volume-title":"Quality assessment tool for observational cohort and cross-sectional studies","author":"NIH National Heart and Blood Institute L","year":"2018","unstructured":"NIH National Heart and Blood Institute L. Quality assessment tool for observational cohort and cross-sectional studies. 2018. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools LB - OcgUV."},{"key":"1528_CR26","doi-asserted-by":"publisher","first-page":"e186007","DOI":"10.1001\/jamanetworkopen.2018.6007","volume":"2","author":"SE Hadland","year":"2019","unstructured":"Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerd\u00e1 M. Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Netw Open. 2019;2:e186007.","journal-title":"JAMA Netw Open"},{"key":"1528_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"1528_CR28","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (Table 7.7.a: formulae for combining groups)","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (Table 7.7.a: formulae for combining groups). 2011. https:\/\/handbook-5-1.cochrane.org\/chapter_7\/table_7_7_a_formulae_for_combining_groups.htm LB - 5yx3V."},{"key":"1528_CR29","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (Section 9.5.2: identifying and measuring heterogeneity)","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (Section 9.5.2: identifying and measuring heterogeneity). 2011. https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_5_2_identifying_and_measuring_heterogeneity.htm LB - 2Eqzt."},{"key":"1528_CR30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/add.14068","volume":"113","author":"HY Chang","year":"2018","unstructured":"Chang HY, Murimi IB, Jones CM, Alexander GC. Relationship between high-risk patients receiving prescription opioids and high-volume opioid prescribers. Addiction. 2018;113:677\u201386.","journal-title":"Addiction."},{"key":"1528_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3109\/15360288.2013.846957","volume":"27","author":"CR Chapman","year":"2013","unstructured":"Chapman CR, Bradshaw DH. Only modest long-term opioid dose escalation occurs over time in chronic nonmalignant pain management. J Pain Palliat Care Pharmacother. 2013;27:370\u20137. https:\/\/doi.org\/10.3109\/15360288.2013.846957.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1528_CR32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jpain.2012.09.003","volume":"13","author":"AM Kobus","year":"2012","unstructured":"Kobus AM, Smith DH, Morasco BJ, Johnson ES, Yang X, Petrik AF, et al. Correlates of higher-dose opioid medication use for low back pain in primary care. J Pain. 2012;13:1131\u20138. https:\/\/doi.org\/10.1016\/j.jpain.2012.09.003.","journal-title":"J Pain"},{"key":"1528_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5055\/jom.2019.0482","volume":"15","author":"BJ Morasco","year":"2019","unstructured":"Morasco BJ, Dobscha SK, Hyde S, Mitchell SH. Exploratory study examining associations between prescription opioid dose and delay discounting in patients with chronic pain. J Opioid Manag. 2019;15:19\u201325. https:\/\/doi.org\/10.5055\/jom.2019.0482.","journal-title":"J Opioid Manag"},{"key":"1528_CR34","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/pme.12773","volume":"16","author":"G Campbell","year":"2015","unstructured":"Campbell G, Nielsen S, Larance B, Bruno R, Mattick R, Hall W, et al. Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort. Pain Med. 2015;16:1745\u201358. https:\/\/doi.org\/10.1111\/pme.12773.","journal-title":"Pain Med"},{"key":"1528_CR35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/pds.4366","volume":"27","author":"DT Coyle","year":"2018","unstructured":"Coyle DT, Pratt C-Y, Ocran-Appiah J, Secora A, Kornegay C, Staffa J. Opioid analgesic dose and the risk of misuse, overdose, and death: a narrative review. Pharmacoepidemiol Drug Saf. 2018;27:464\u201372. https:\/\/doi.org\/10.1002\/pds.4366.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1528_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.7861\/clinmed.2019.0227","volume":"19","author":"J Quinlan","year":"2019","unstructured":"Quinlan J, Rann S, Bastable R, Levy N. Perioperative opioid use and misuse. Clin Med. 2019;19:441\u20135.","journal-title":"Clin Med"},{"key":"1528_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.pain.2010.08.036","volume":"151","author":"MD Sullivan","year":"2010","unstructured":"Sullivan MD. Who gets high-dose opioid therapy for chronic non-cancer pain? Pain. 2010;151:567\u20138. https:\/\/doi.org\/10.1016\/j.pain.2010.08.036.","journal-title":"Pain."},{"key":"1528_CR38","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.bja.2018.03.002","volume":"120","author":"CF Stannard","year":"2018","unstructured":"Stannard CF. Pain and pain prescribing: what is in a number? Br J Anaesth. 2018;120:1147\u20139. https:\/\/doi.org\/10.1016\/j.bja.2018.03.002.","journal-title":"Br J Anaesth"},{"key":"1528_CR39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.31887\/DCNS.2002.4.3\/jcottraux","volume":"4","author":"J Cottraux","year":"2002","unstructured":"Cottraux J. Nonpharmacological treatments for anxiety disorders. Dialogues Clin Neurosci. 2002;4:305\u201319.","journal-title":"Dialogues Clin Neurosci"},{"key":"1528_CR40","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jamainternmed.2017.2468","volume":"177","author":"JM Liebschutz","year":"2017","unstructured":"Liebschutz JM, Xuan Z, Shanahan CW, La Rochelle M, Keosaian J, Beers D, et al. Improving adherence to long-term opioid therapy guidelines to reduce opioid misuse in primary care: a cluster-randomized clinical trial. JAMA Intern Med. 2017;177:1265\u201372.","journal-title":"JAMA Intern Med"},{"key":"1528_CR41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/AJP.0000000000000177","volume":"31","author":"D Anderson","year":"2015","unstructured":"Anderson D, Zlateva I, Khatri K, Ciaburri N. Using health information technology to improve adherence to opioid prescribing guidelines in primary care. Clin J Pain. 2015;31:573\u20139. https:\/\/doi.org\/10.1097\/AJP.0000000000000177.","journal-title":"Clin J Pain"},{"key":"1528_CR42","doi-asserted-by":"publisher","first-page":"e182908","DOI":"10.1001\/jamanetworkopen.2018.2908","volume":"1","author":"BR Meisenberg","year":"2018","unstructured":"Meisenberg BR, Grover J, Campbell C, Korpon D. Assessment of opioid prescribing practices before and after implementation of a health system intervention to reduce opioid overprescribing. JAMA Netw Open. 2018;1:e182908.","journal-title":"JAMA Netw Open"},{"key":"1528_CR43","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","volume":"356","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760. https:\/\/doi.org\/10.1136\/bmj.j760.","journal-title":"BMJ."},{"key":"1528_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/pme.12907","volume":"17","author":"N Dasgupta","year":"2016","unstructured":"Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17:85\u201398. https:\/\/doi.org\/10.1111\/pme.12907.","journal-title":"Pain Med"},{"key":"1528_CR45","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376:1147\u201357. https:\/\/doi.org\/10.1056\/NEJMra1611832.","journal-title":"N Engl J Med"},{"key":"1528_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2049463717742420","volume":"12","author":"R Ponton","year":"2018","unstructured":"Ponton R, Sawyer R. Opioid prescribing in general practice: use of a two-stage review tool to identify and assess high-dose prescribing. Br J Pain. 2018;12:171\u201382. https:\/\/doi.org\/10.1177\/2049463717742420.","journal-title":"Br J Pain"},{"key":"1528_CR47","doi-asserted-by":"publisher","unstructured":"Bastable R, Rann S. Opioids aware: a general practice audit of high-dose opioid prescribing NHS England Midlands and East. BJGP Open. 2019;3(2):bjgpopen18X101642. https:\/\/doi.org\/10.3399\/bjgpopen18X101642.","DOI":"10.3399\/bjgpopen18X101642"},{"key":"1528_CR48","doi-asserted-by":"publisher","first-page":"e0221438","DOI":"10.1371\/journal.pone.0221438","volume":"14","author":"M Mofizul Islam","year":"2019","unstructured":"Mofizul Islam M, Wollersheim D. A comparison of opioids and benzodiazepines dispensing in Australia. PLoS One. 2019;14:e0221438. https:\/\/doi.org\/10.1371\/journal.pone.0221438.","journal-title":"PLoS One"},{"key":"1528_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1370\/afm.1885","volume":"14","author":"JF Scherrer","year":"2016","unstructured":"Scherrer JF, Salas J, Copeland LA, Stock EM, Ahmedani BK, Sullivan MD, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med. 2016;14:54\u201362.","journal-title":"Ann Fam Med"},{"key":"1528_CR50","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1097\/j.pain.0000000000001305","volume":"159","author":"G Mazereeuw","year":"2018","unstructured":"Mazereeuw G, Sullivan MD, Juurlink DN. Depression in chronic pain: might opioids be responsible? Pain. 2018;159:2142\u20135.","journal-title":"Pain."},{"issue":"13 Suppl","key":"1528_CR51","first-page":"S243","volume":"25","author":"DL Leslie","year":"2019","unstructured":"Leslie DL, Ba DM, Agbese E, Xing X, Liu G. The economic burden of the opioid epidemic on states: the case of Medicaid. Am J Manag Care. 2019;25(13 Suppl):S243\u20139.","journal-title":"Am J Manag Care"},{"key":"1528_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13012-018-0719-8","volume":"13","author":"EE McGinty","year":"2018","unstructured":"McGinty EE, Stuart EA, Caleb Alexander G, Barry CL, Bicket MC, Rutkow L. Protocol: mixed-methods study to evaluate implementation, enforcement, and outcomes of U.S. state laws intended to curb high-risk opioid prescribing. Implement Sci. 2018;13:37. https:\/\/doi.org\/10.1186\/s13012-018-0719-8.","journal-title":"Implement Sci"},{"issue":"691","key":"1528_CR53","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.3399\/bjgp19X707237","volume":"70","author":"Lauren J Scott","year":"2019","unstructured":"Scott LJ, Kesten JM, Bache K, Hickman M, Campbell R, Pickering AE, et al. Evaluation of a primary care-based opioid and pain review service: a mixed-methods evaluation in two GP practices in England. Br J Gen Pract. 2019. https:\/\/doi.org\/10.3399\/bjgp19X707237.","journal-title":"British Journal of General Practice"},{"issue":"10028","key":"1528_CR54","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(16)00161-6","volume":"387","author":"Stefano Berterame","year":"2016","unstructured":"Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387(10028):1644\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(16)00161-6.","journal-title":"The Lancet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01528-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-020-01528-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01528-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T23:32:41Z","timestamp":1617060761000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01528-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01528-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"assertion":[{"value":"16 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GCR is funded by the NIHR SPCR Research Doctoral Studentship, the Naji Foundation, and the Rotary Foundation. KRM has received funding from NIHR and the Royal College of General Practitioners (RCGP) to conduct independent research. TBM is financially supported by the Rhodes Trust to study for a Doctor of Philosophy. NJD is employed on BG\u2019s grants from the Laura and John Arnold Foundation and is financially supported by the Naji Foundation to study for a Doctor of Philosophy. CK is funded by the NIHR SPCR and the Wellcome Trust\/Royall Society Sir Henry Dale Fellowship. JKA has written papers on adverse drug reactions in peer-reviewed journals and has received royalties from textbooks that he has edited or co-edited. JKA has often acted as an expert witness in cases involving adverse drug reactions, most often in Coroners\u2019 courts. BG receives funding from the Health Foundation, the NIHR SPCR, the NIHR Biomedical Research Centre Oxford, and the NHS England for work on UK prescribing data. BG has additionally received funding from the Laura and John Arnold Foundation, the Wellcome Trust, and WHO to work on better use of data in medicine and receives personal income from speaking and writing for lay audiences on the misuse of science. CJH has received funding from the WHO, FDA, NIHR, NIHR SPCR, and NIHR BRC Oxford; received expenses and fees for his media work (including payments from BBC Radio 4 Inside Health), remuneration from an asbestos case and given free legal advice on mesh cases, income from the publication of a series of toolkit books published by Blackwells, and expenses for teaching EBM; and is also paid for his GP work in NHS out of hours (contract with Oxford Health NHS Foundation Trust). CJH is the Director of CEBM, which jointly runs the EvidenceLive Conference with the BMJ and the Overdiagnosis Conference with international partners, based on a non-profit making model. CJH is the Editor in Chief of BMJ Evidence-Based Medicine and is an NIHR Senior Investigator.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}